Lycia Therapeutics (LYCA) vs Windward Bio Group (WWB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lycia Therapeutics is the larger company by market cap ($1.72 billion vs $1.45 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LYCA | WWB |
|---|---|---|
| Share price | $33.07 | $24.29 |
| Market cap | $1.72B | $1.45B |
| 1-day change | +4.09% | +1.15% |
| EPS (TTM) | $-1.04 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.49 | $33.99 |
| 52-week low | $22.19 | $18.35 |
| Distance from 52-week high | -9.37% | -28.55% |
| Average volume | 432.72K | 434.33K |
| Shares outstanding | 52.09M | 59.58M |
| Employees | 31 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Lycia Therapeutics
LYCA stock →Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31 employees
About Windward Bio Group
WWB stock →Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 33 employees
LYCA vs WWB FAQ
Which is bigger, Lycia Therapeutics or Windward Bio Group?
Lycia Therapeutics (LYCA) is larger, with a market capitalization of $1.72B compared with $1.45B for Windward Bio Group (WWB).
Are Lycia Therapeutics and Windward Bio Group in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.